Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC. (IMMU)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CET
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at [email protected]

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
01/19 IMMUNOMEDICS : Data on Monoclonal Antibodies Discussed by Researchers at Immunom..
01/19 IMMUNOMEDICS : Findings from Immunomedics, Inc. Has Provided New Data on Melanom..
01/12 IMMUNOMEDICS : Announces Agreement with University of Wisconsin Carbone Cancer C..
01/11 Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer ..
01/10 IMMUNOMEDICS, INC. : Today’s Research Reports on Stocks to Watch: Immunomedics, ..
01/09 IMMUNOMEDICS : and Royalty Pharma Announce Royalty Funding and Stock Purchase Ag..
01/08 IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Unregistered Sale..
01/08 Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase A..
01/04 Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference
2017 IMMUNOMEDICS : Entry into a Material Definitive Agreement (form 8-K/A)
More news
News from SeekingAlpha
01/12 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 12, 2018
01/12 Immunomedics (IMMU) Presents At 36th Annual J.P. Morgan Healthcare Conference..
01/12 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 11, 2018
01/11 Immunomedics to fund mid-stage study of sacituzumab govitecan in CRPC
01/10 When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
Financials ($)
Sales 2018 14,9 M
EBIT 2018 -101 M
Net income 2018 -197 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 164x
Capi. / Sales 2019 60,0x
Capitalization 2 431 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 18,3 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Michael Pehl President & Chief Executive Officer
Behzad Aghazadeh Chairman
Michael R. Garone Chief Financial Officer & Vice President
William A. Wegener Chief Medical Officer
David M. Goldenberg Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.-1.05%2 431
CELLTRION, INC.--.--%33 774
IQVIA HOLDINGS INC2.37%21 423
LONZA GROUP0.76%20 876
INCYTE CORPORATION-4.65%19 660
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 275